The BEST Trial, a randomized study comparing PCI with everolimus-eluting stents to CABG, provides valuable insights into the long-term cardiovascular outcomes in patients with multivessel CAD. While the initial results favored CABG, the BEST Extended Follow-Up Study demonstrates that advances in PCI procedures have narrowed the gap. However, the mortality benefit of CABG requires further investigation, emphasizing the importance of individualized patient discussions.